Lucas K G, Pollok K E, Emanuel D J
Department of Pediatrics, Riley Hospital for Children, Indiana University, Indianapolis 46202-5225, USA.
Leuk Lymphoma. 1997 Mar;25(1-2):1-8. doi: 10.3109/10428199709042491.
Epstein Barr virus induced lymphoproliferative disease (EBV-LPD) is a heterogeneous disorder, ranging from polyclonal lymphoproliferations to malignant lymphoma, typically seen in individuals with inadequate cellular immunity to EBV. The diagnosis of EBV-LPD following transplant requires a high index of suspicion in those patients at risk. Unlike organ transplant patients, in whom lymphomas are generally of host origin and respond to decreases in immunosuppression, bone marrow transplant recipients have donor origin tumors that are not as responsive to conservative treatment modalities. For the latter group, adoptive immunotherapy with donor lymphocytes is the treatment of choice and generally results in complete eradication of these tumors. Whether adoptive immunotherapy can be used for EBV-LPD in patients following organ transplantation is currently being investigated.
爱泼斯坦-巴尔病毒诱导的淋巴增殖性疾病（EBV-LPD）是一种异质性疾病，范围从多克隆淋巴增殖到恶性淋巴瘤，通常见于对EBV细胞免疫不足的个体。移植后EBV-LPD的诊断需要对有风险的患者保持高度怀疑。与器官移植患者不同，器官移植患者的淋巴瘤通常起源于宿主且对免疫抑制的降低有反应，而骨髓移植受者的肿瘤起源于供体，对保守治疗方式的反应不佳。对于后一组患者，采用供体淋巴细胞进行过继性免疫治疗是首选治疗方法，通常可使这些肿瘤完全消除。目前正在研究过继性免疫治疗是否可用于器官移植后患者的EBV-LPD。
